This Week in Pulmonary — Sep 22, 2026

Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning chronic airway infection and bronchiectasis care, COPD phenotyping and rehabilitation, and a set of papers on diagnostics, epidemiology and sleep-disordered breathing. Let's dive in.

We start with chronic airway infection, where three papers together suggest our antibiotic strategies may be aging badly. In Chest, Muhlebach and colleagues interrogated nearly a decade of United States Cystic Fibrosis Foundation registry data, from about twelve thousand people in 2011 to just over sixteen thousand in 2019, asking whether chronic inhaled antibiotics still earn their place now that CFTR modulators have transformed outcomes [1]. Two findings deserve attention. First, people prescribed inhaled antibiotics had roughly a third higher risk of new Aspergillus infection, and about a fifth to a quarter higher risk of Stenotrophomonas maltophilia and Achromobacter, and that excess risk was greatest in those who were Pseudomonas negative. Second, the lung function benefit tracked infection status almost perfectly in the wrong direction: inhaled antibiotics were associated with better lung function in chronic Pseudomonas, but worse lung function in Pseudomonas negative patients. And in those with chronic Pseudomonas, the antibiotic-associated benefit shrank across successive modifier eras. This is observational and weighted analysis rather than a trial, so causal claims are limited, but the practical signal is hard to ignore: continuing chronic inhaled antibiotics in someone who no longer cultures Pseudomonas may be all risk and no reward.

That concern gets sharper alongside a Thorax paper from Pitts and colleagues, who assembled over one hundred and ten thousand respiratory samples from more than nineteen thousand people with bronchiectasis or cystic fibrosis across eleven cities and eight countries [2]. Resistance is rising, not plateauing. In bronchiectasis, Pseudomonas resistance climbed year on year across four centres for aminoglycosides, fluoroquinolones, cephalosporins, beta-lactam inhibitor combinations and carbapenems. Multidrug resistance was strikingly common in emergent Gram negatives — around a third of Escherichia coli isolates in cystic fibrosis and closer to forty percent in bronchiectasis. And critically, among people with cystic fibrosis who remained culture positive on triple modifier therapy, the multiple antibiotic resistance index rose significantly. So modulators have not made resistance someone else's problem. There was also marked geographic variation, with more Pseudomonas resistance in central and southern Europe and more Klebsiella resistance in Hong Kong — an argument for local, not imported, antibiograms.

Meanwhile the denominator keeps growing. Also in Chest, Jung and MacRae used the Epic Cosmos record database, drawing on a 2025 primary care population of over fifty-eight million adults, and identified more than one hundred and ninety thousand patients meeting a code and imaging based definition of non-cystic fibrosis bronchiectasis [3]. Age-adjusted prevalence was about two hundred and seventy per hundred thousand, and it rose by roughly one hundred and thirty percent over the decade. These patients were markedly older, average age seventy-two versus fifty-eight, predominantly female, and overwhelmingly Medicare-insured. Some of that rise is genuine recognition and more chest computed tomography rather than more disease, but the workload is real. Which is why a companion perspective in Chest from MacRae and colleagues is worth reading, proposing a practical framework for delivering bronchiectasis and nontuberculous mycobacterial care in safety-net systems [4]. Their point is that our guidelines quietly assume prompt subspecialty access, advanced microbiology and expensive drugs, and they offer four domains — earlier diagnostic pathways, co-management that triages the highest-risk patients to expertise, pragmatic therapy choices matched to available resources, and language and culturally appropriate education.

Turning to COPD, the theme is better phenotyping and better rehabilitation. In Chest, Li and colleagues followed two hundred and fifteen patients with COPD, stratifying them on quantitative computed tomography by mucus plug score and emphysema extent [5]. Compared with patients who had little mucus and little emphysema, all three other groups had roughly a threefold higher adjusted risk of acute exacerbation, and each one-point rise in mucus plug score carried about a ten percent higher exacerbation risk. Interestingly, the mucus plug signal was only statistically significant in patients with limited emphysema — suggesting that in emphysema-dominant disease, plugging adds little prognostic information. With cohorts of this size the estimates are imprecise, but if your centre already generates quantitative computed tomography metrics, mucus plugging looks like a cheap and potentially modifiable risk marker.

On the rehabilitation side, Thorax published a multicentre, double-blind, placebo-controlled trial from Maniscalco and colleagues in ninety-eight patients with advanced COPD and chronic respiratory failure on long-term oxygen, testing whether oral L-arginine plus liposomal vitamin C reduces fatigue during a twenty-eight day rehabilitation programme [6]. Fatigue Severity Scale scores fell significantly more in the active group, by about nine tenths of a point, which edges past the prespecified minimal clinically important difference of zero point six. But be careful how you read this: every secondary outcome — six minute walk distance, sit-to-stand, handgrip, the COPD Assessment Test and dyspnoea score — showed no significant between-group difference, and the higher proportion of patients reaching a Fatigue Severity Scale below four did not reach statistical significance. So this is a modest, single-domain, patient-reported signal in a small trial, not a reason to start stocking supplements.

A far larger effect came from a single-centre, assessor-blinded randomised trial in Chest by Liu and colleagues, in one hundred and fifty patients aged eighty or older on prolonged mechanical ventilation, comparing a multicomponent pulmonary rehabilitation programme with standard rehabilitation [7]. Successful weaning occurred in about forty-five percent of the intervention patients versus twelve percent of controls — roughly a fivefold higher rate of liberation, and the competing-risk analysis held up. The intervention group also did better on oxygen saturation off the ventilator, diaphragm thickening fraction, cough strength and muscle strength, and had less ventilator-associated pneumonia at sixty and ninety days. Deep vein thrombosis rates did not differ, and mortality was low and similar in both arms. This is one centre with a very low baseline weaning rate, so the absolute gains may not transfer, but the direction of effect in the oldest, most deconditioned ventilated patients is striking.

Three remaining papers address diagnostics, epidemiology and sleep. In Chest, Bridwell and colleagues modelled the cost-effectiveness of thoracentesis with cytology versus medical thoracoscopy with pleural biopsy in patients with prior or active malignancy [8]. For a first unilateral effusion, thoracoscopy-first avoided a small number of complications but cost nearly two thousand dollars more per patient, so thoracentesis remains the cost-effective opener whenever expected cytology sensitivity exceeds roughly twenty-seven percent — true for most tumour types. But after one cytology-negative thoracentesis, thoracoscopy next cost only about nineteen dollars more while avoiding more complications, making it the preferred second step rather than repeating the tap. Then in Thorax, Ma and colleagues analysed Burden of Obstructive Lung Disease data from over twenty-eight thousand adults born between 1902 and 1976 across forty-one sites in thirty-four countries, and found that each later birth year was associated with higher forced vital capacity, higher FEV1 and a higher ratio, consistent across sex, smoking status and both high-income and lower-income countries [9]. Successive generations have better lungs — a reminder that reference equations built on older cohorts may misclassify today's patients. And finally, a Chest review by Brill and colleagues makes the case that central sleep apnea and Cheyne-Stokes respiration after stroke are common but underrecognised, largely because they rarely occur in isolation and are overshadowed by obstructive events [10].

If you only have time for one paper this week, make it the inhaled antibiotic analysis in Chest [1]. It directly challenges a prescribing habit many of us continue indefinitely, and it identifies exactly which patients — those who are Pseudomonas negative — are absorbing the harms without the benefit.

Here are the key takeaways from this week in Pulmonary. First, revisit chronic inhaled antibiotics in cystic fibrosis patients who no longer culture Pseudomonas, where harms appear to outweigh any lung function benefit. Second, resistance in bronchiectasis and cystic fibrosis is rising internationally and persists on triple modifier therapy, so use local rather than borrowed resistance data. Third, bronchiectasis prevalence in United States primary care has more than doubled over a decade, concentrated in older women on Medicare, and delivery models in under-resourced systems need to adapt. Fourth, quantitative computed tomography mucus plugging predicts exacerbations, particularly in patients without extensive emphysema. Fifth, structured multicomponent rehabilitation substantially improved ventilator liberation in patients over eighty, while an arginine and vitamin C supplement reduced only self-reported fatigue with no functional gain. And finally, after a cytology-negative thoracentesis for suspected malignant effusion, go to thoracoscopy rather than a repeat tap.

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.